Scientific Program
The Education Program, sponsored jointly by the Congress and the Scientific and Standardization Committee, and the Scientific and Standardization Committee sessions will be held on Saturday 8 AM – 6 PM and Sunday 8 AM - 12 Noon. Education Programs will be a part of individual SSC sessions, and will supplement topics not addressed in the main ISTH program. Speakers will provide attendees with an introduction to, and fundamentals of a given subject. For more information on these meetings please contact:
|
||||||||
Educational Program Sessions include (as of December, 2008):
Saturday 8:00 AM - 9:30 AM |
|
| Hemostasis and Malignancy |
|
| Frederick R. Rickles, MD, FACP | Coagulation as a biological target for cancer therapy |
| Alok A. Khorana, MD | Predicting cancer patients at risk for venous thromboembolism: Strategies for Prophylaxis |
| Agnes Y Lee, MD, MSc, FRCPC | Diagnosis and management of cancer-associated thrombosis |
| Shed proteins/receptors as clinical biomarkers of vascular disease | |
| Lawrence Brass, MD, PhD | Exploring the platelet sheddome |
| Michael Berndt, PhD | Translating the mechanism of GPVI shedding: soluble GPVI as a clinical biomarker |
| Simone Schoenwaelder, PhD | Platelet aging and ectodomain shedding |
| Predictive hemostatic variables: A user's guide to applying clinical/ laboratory predictors of venous and arterial thromboembolism in everyday clinical practice | |
| Mark Woodward, MD | Interpreting studies of predictor variables and clinical outcomes: what does having a risk factor really mean? |
| Marc A. Rodger, MD | Developing a clinical-laboratory prediction rule for recurrent venous thromboembolism: how do we get there? |
| Henri Bounameaux, MD | Interpreting clinical-laboratory prediction rules: when is a Clinical Practice Guideline ready for prime time? |
| Saturday 10:30 AM - 12:00 PM | |
| Women's Health | |
| Claire S. Philipp, MD | Menorrhagia in Women with Bleeding Disorders |
| Benjamin Brenner, MD | Anticoagulation During Pregnancy/ Debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (Yes) |
| Marc A. Rodger, MD | Anticoagulation During Pregnancy/ Debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (No) |
| Saturday 11:00 AM - 12:00 PM | |
| Platelet Immunology | |
| Richard Aster, MD | Drug-induced immune thrombocytopenias |
| Theodore E. Warkentin, MD | Laboratory testing for heparin-induced thrombocytopenia |
Saturday 12:15 PM - 1:45 PM |
|
| APSTH-ISTH Symposium |
|
| Pantep Angchaisuksiri, MD |
Coagulopathy in Malaria |
| Takashi Morita, PhD |
Use of Asian snake venom inhibitors in studies of blood coagulation mechanism |
| Geoff Isbister, MD |
Coagulopathy induced by snake bites and its management |
| Toshiyuki Miyata, PhD |
Genetic disorders related to coagulopahty prevalent in the Far East |
| Introduction to Genomics and Molecular Epidemiology |
|
| Willem Owehand, MD |
Introduction to Gemonics and Molecular Epidemiology |
| In silico drug design |
|
| Speakers TBA |
|
| Developing clinical practice guidelines – GRADE system experiences |
|
| Roman Jaeschke, MD |
Consensus practice guidelines: How are they developed? What is their aim? How successful are they in knowledge translation and changing practice? |
| Gordon Lowe, MD | Incorporating practice guidelines into the realm of arterial and venous thromboembolism predictors: What do we have? What is missing? |
Saturday 2:00 PM - 3:00 PM |
|
| Fibrinogen/Factor XIII |
|
| John Weisel, MD |
Fibrin gels and bioengineering/clinical applications |
| Aida Inbal, MD | Non-coagulation activities of Factor XIII |
Saturday 2:00 PM - 3:30 PM |
|
| Plasma Coagulation Inhibitors |
|
| Speakers TBA |
|
| Factor VIII & IX |
|
| Kathelijn Fischer, MD |
Management of hemophilia and assessment of outcomes |
| Edward GD Tuddenham, MD | Factor concentrates for hemophilia - current products and newer technologies |
| Arun Srivastava, PhD | Gene therapy in hemophilia: overview and new possibilities |
| Perinatal/Pediatric Hemostasis |
|
| Gili Kenet, MD |
Developmental Hemostasis |
| Ulrike Nowak-Gottl, MD |
Pediatric venous thromboembolism and thrombophilia |
| Paul Monagle, MD | Anticoagulant therapy in children |
Saturday 4:30 PM - 6:00 PM |
|
| Animal Models |
|
| Thomas G. Diacovo MD | Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies |
| Eva-Marie Muchitsch | Key questions for animal models of hemostasis in developing new drugs and obtaining approval |
| Mortimer Poncz, MD |
Stressing the limits of mice models of hemophilia: when mice are not small people |
| Lupus Anticoagulant/ Phospholipid-dependent Antibodies |
|
| Thomas Ortel, MD PhD |
Historical background |
| Jacob H. Rand, MD |
Mechansims of action of antiphosopholipid antibodies |
| Ph G de Groot, PhD |
Laboratory diagnosis |
| Vittorio Pengo, MD |
Clinical features |
| Biorheology |
|
| Speakers TBA | |
| Sunday 8:00 AM - 9:30 AM | |
| Disease-Specific Molecular Mechanisms in Disseminated Intravascular Coagulation (DIC) | |
| Peter A. Ward, MD | Role of IL-17 in Sepsis |
| Karim Brohi, MD | New Concepts in Trauma Induced Coagulopathy |
| Katherine A. Hajjar, MD | Acute Promyelocytic Leukemia: Mechanisms of Coagulopathy |
| Von Willebrand Disease (VWD) Diagnosis | |
| Francesco Rodeghiero, MD | Clinical aspects of VWD diagnosis |
| Robert R Montgomery, MD | Laboratory testing of the hemostasis phenotype in VWD |
| Anne Goodeve, MD | Genetic analysis as an aid in VWD diagnosis |
Sunday 10:30 AM - 12:00 AM |
|
| Control of Anticoagulation |
|
| Speakers TBA |
|
| Fibrinolysis/ D-dimer |
|
| Carl-Eric Dempfle, MD |
D-dimer in the emergency room (venous thromboembolism exclusion, aortic dissection) |
| Wolfgang Korte, MD |
Fibrin generation markers in the perioperative setting |
| Saskia Middledorp, MD PhD | D-dimer as prognostic parameter in venous thromboembolism, pregnancy and cancer |
| Sunday 11:00 AM - 12:00 PM | |
| Platelet Physiology |
|
| Alan D Michelson, MD |
Platelet function as a Guide to Thrombotic Risk |
| Catherine P M Hayward, MD | Recent advances in the understanding and diagnosis of inherited platelet function disorders |
| Plasma Kallikrein System | |
| Speakers TBA | |